Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Potassium chloride, Glucose monohydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for This medicine contains a solution of potassium chloride and glucose. It is administered to you through a tube placed into a vein (intravenous drip). You will receive it to maintain or restore your potassium levels and to cover your basic energy requirements.
What you need to know before you take it
e this medicine Do not use Potassium Chloride 0.15% w/v and Glucose 5% w/v
- if you have too high levels of potassium or chloride in your blood (hyperkalaemia or severe hyperchloremia)
- if you have severe kidney disease
- if you have had a head injury (during the first 24 hours)
- if you have too much water in your body (hyperhydration)
- if you have too high blood sugar levels (hyperglycaemia) Warnings and precautions Talk to your doctor before you are given Potassium Chloride 0.15 % w/v and Glucose 5% w/v. Before or when giving you this medicine, your doctor will pay attention to the following: •
Kidney function: You will receive this medicine as a slow intravenous drip after your doctor has made sure that your kidneys are working properly. If you have problems with your kidneys, your potassium, blood
levels and your ECG will be monitored while you receive this medicine. Your doctor will make sure to stop the infusion in case your condition worsens. •
Heart disease: If you suffer from heart disease, this medicine will be given to you with caution.
•
Swelling of the lower limbs or water on your lungs (pulmonary oedema): If you have one of these conditions, special care should be taken if you will be given large amounts of this medicine.
•
Levels of salts in your blood: When given this medicine, patients who are acutely ill, with pain, postoperative stress, infections, burns, diseases of the nervous system, heart, liver or kidney, and patients who are on medicines working like vasopressin (a hormone which regulates the amount of body fluids), are at particular risk of developing an abnormally low level of sodium in the blood (acute hyponatraemia) which can lead to a life-threatening swelling of the brain (hyponatraemic encephalopathy, brain oedema). Women of childbearing potential and patients with serious brain conditions such as an infection of the membranes surrounding the brain (meningitis) or brain injury (intracranial bleeding, cerebral contusion) are at particular risk of the severe and life-threatening brain swelling caused by an abnormally low level of sodium in the blood. To avoid too low blood levels of sodium (hyponatraemia), appropriate amounts of sodium may be given additionally.
•
Certain types of diabetes: This medicine will be given to you with caution
- if you have diabetes
- in other conditions where your body is unable to process sugars as normal (e.g. if you are taking certain medicines, see also section 'Other medicines and Potassium Chloride 0.15 % w/v and Glucose 5% w/v' below) Your blood sugar levels will be monitored.
•
Blood transfusions You will not be given this medicine together with, immediately before or after blood through the same tubing.
•
After you have had a stroke You should normally not receive this medicine if you suffer or have recently suffered from stroke except if your doctor considers it essential for your recovery.
•
Too much potassium in your blood If you have a disease where potassium levels are too high in your blood such as Addison's disease (a specific disease of the adrenal gland), or sickle cell anaemia (an inherited disease of the red blood cells).
Your ECG, your fluid balance, the salts in your blood and your level of glucose will be checked regularly while you are receiving this medicine. Adequate supply of vitamins (in particular vitamin B1) will be ensured. Elderly patients, who are more likely to suffer from heart and kidney problems, will be closely monitored during treatment and the dosage will be carefully adjusted.
Children Children are at particular risk of the severe and life-threatening brain swelling caused by an abnormally low level of sodium in the blood. This medicine will be given to children only with special caution. In addition, their salt and fluid balance will be closely checked. Other medicines and Potassium Chloride 0.15% w/v and Glucose 5% w/v Tell your doctor if you are taking, have recently taken or might take any other medicine. If you are taking digoxin or similar medicines that help your heart to work better, tell your doctor as it may change how they work. The amount of Potassium Chloride 0.15 % w/v and Glucose 5% w/v may have to be adjusted. Also tell your doctor if you are taking medicines that contain potassium or may lead to high potassium levels, such as:
- potassium-sparing medicines e.g. spironolactone or triamterene (medicines that increase urine flow)
- ACE inhibitors (medicines to treat high blood pressure or heart failure)
- Angiotensin II receptor antagonists (a type of antihypertensive medicine)
- non-steroidal anti-inflammatory agents (for acute or chronic conditions of pain and inflammation)
- cyclosporine, tacrolimus (medicines that are used after an organ transplant)
- suxamethonium (a medicine that is used during anaesthesia). They will take special care of you if you receive/take medicines that make you retain potassium as these may lead to heart problems (cardiac arrhythmia). If you are taking certain medicines, namely corticosteroids, ACTH and loop diuretics your renal elimination of potassium can be increased. Your doctor will only administer this solution with caution if you are taking one of the following medicines that work like vasopressin or increase the effect of vasopressin and increase the risk of low blood sodium levels (hyponatraemia):
- Carbamazepine and oxcarbazepine, used to treat epilepsy
- Clofibrate, used to treat high blood fat levels
- Vincristine and ifosfamide, used as anticancer treatments
- Cyclophosphamide, used to treat cancer and autoimmune diseases
- Selective Serotonin Reuptake Inhibitors (SSRIs), used to treat depression
- Antipsychotics, used to treat mental health disorders
- Opioid pain killers, used to relieve severe pain
- Non-steroidal anti-inflammatory drugs (NSAIDs), used to relieve mild to moderate pain and to treat inflammation in your body
- Chlorpropamide, used to treat diabetes mellitus (high blood sugar levels after meals)
- Desmopressin, used to treat diabetes insipidus (extreme thirst and the continuous production of large volumes of dilute urine)
- Oxytocin, used during labour
- Vasopressin and Terlipressin, used to treat 'bleeding oesophageal varices' (enlarged veins in your food pipe caused by liver problems)
- 3,4-methylenedioxy-N-methamphetamine, (MDMA, 'ecstasy'), an illegal drug
- Diuretics or water tablets (medicines which increase the amount of urine)' Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. This medicine can be given while you are pregnant or breast-feeding if your doctor considers it necessary. Driving and using machines Potassium Chloride 0.15 % w/v and Glucose 5% w/v has no influence on the ability to drive or use machines.
How to take it
Potassium Chloride 0.15% w/v and Glucose 5% w/v Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. Your doctor may monitor fluid balance, glucose and electrolyte levels (including sodium) in your blood before and during treatment, especially in patients with increased production of vasopressin (a hormone which regulates the amount of body fluids) and in patients who are on medicines working like vasopressin, because there is a risk of an abnormally low sodium level in your blood (hyponatraemia). See also sections "Warnings and precautions", "Other medicines and Potassium Chloride 0.15 % w/v and Glucose 5% w/v" and "Possible side effects". Dose The recommended dose that you will be given will be determined by your doctor. It will depend on your age, weight and condition, especially if your heart or kidneys do not work properly. While you receive this medicine your blood glucose and electrolyte (salt) levels, water balance and ECG will be checked regularly. Your doctor will make sure that your urine flow is sufficient. The recommended maximum dose for an adult is 40 ml/kg body weight/day. In cases where more potassium is needed, your doctor will take into consideration other strengths as well. This medicine may be given to you as long as you need energy, salts and fluid by an infusion. Elderly In principle, the same dose as for adults can be used. However, in older people it might be necessary to adjust the dose stated to avoid circulatory and kidney problems. Use in children and adolescents In children and adolescents the dose will depend upon the individual needs. They may receive a reduced dose. Method of administration This medicine will be administered to you through a tube placed into a vein (intravenous drip). If you receive more Potassium Chloride 0.15% w/v and Glucose 5% w/v than you should It is unlikely that this occurs because your doctor will determine your daily dose. Signs of an overdose If you have received too much of this medicine you may experience disorders of your salt, sugar, water and acid-base balance. You may also experience tissue fluid accumulation and potassium intoxication. Potassium blood levels may especially be excessively increased. Signs of such disorder may be:
• • • • • • •
Low blood pressure (hypotension) Irregular heart beats or your heart stops beating ECG abnormalities up to the heart stops beating General weakness and listlessness Muscle weakness, inability to move Very marked numbness, weakness or heaviness of your legs Confusion.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor if you notice pain, tenderness or inflammation of blood clots at the site of injection. Not known (frequency cannot be estimated from the available data) ● Hospital-acquired abnormally low blood sodium levels (hyponatraemia) ● Brain swelling (brain oedema) due to abnormally low blood sodium levels (hyponatraemic encephalopathy). This may cause irreversible brain damage and death. The symptoms include: headache, feeling sick (nausea), vomiting, seizures, tiredness and lack of energy Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
How to store it
Potassium Chloride 0.15% w/v and Glucose 5% w/v Unopened: Do not store above 25°C. Keep this medicine out of the sight and reach of children. Do not use Potassium Chloride 0.15 % w/v and Glucose 5% w/v after the expiry date which is stated on the labels of the bottles and the carton. The expiry date refers to the last day of that month. Do not use the product if the solution appears cloudy or discoloured, if you find particles in the solution or if the bottle and its closure are damaged. This container is for single use only. After use discard container and any remaining contents.
Contents of the pack and other information
What Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion contains
- The active substances are potassium chloride and glucose. 1 ml of solution for infusion contains 1.5 mg/ml potassium chloride and 50 mg glucose (as glucose monohydrate 55 mg). 1 l of solution for infusion contains 20 mmol potassium and 20 mmol chloride.
- The other ingredient is water for injections. •
Energy Theoretical osmolarity pH approximately
835 kJ/l ≙ 200 kcal/l 318 mOsmol/l 3.5- 6.5
What Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion looks like and contents of the pack Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion is a clear, watery, colourless up to faintly straw-coloured solution of potassium chloride and glucose in water. It comes in plastic (polyethylene) bottles containing 500 ml or 1,000 ml, supplied in packs of 10 x 500 ml and 10 x 1000 ml. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer B. Braun Melsungen AG Carl-Braun-Strasse 1 34212 Melsungen, Germany Postal address 34209 Melsungen Phone: +49-5661-71-0 Fax: +49-5661-4567 Manufacturers B. Braun Melsungen AG Carl-Braun-Straße 1 34212 Melsungen, Germany B. Braun Medical S.A. Carretera de Terrassa 121 08191 Rubi, Barcelona, Spain This leaflet was last revised in 08/2025 __________________________________________________________________________________ The following information is intended for healthcare professionals only: Posology Adults: The following recommendations are general guidelines on potassium. Potassium The amount required for correction of moderate potassium deficiency and in maintenance may be calculated according to the following formula: mmol K+required = (body weight [kg] × 0.2)* × 2 × (serum-K+target** – serum-K+actual [mmol/l])
*Term represents the extracellular fluid volume ** should be 4.5 mmol/l The maximum recommended dose of potassium is 2 – 3 mmol/kg body weight (BW)/24 h. Maximum infusion rate Up to 5 ml/kg body weight per hour, corresponding to 0.25 g glucose/kg body weight per hour and 0.1-0.2 mmol/kg/ body weight per hour potassium (for 0.15% w/v and 0.3% w/v, respectively). Paediatric population Generally a substitution rate of 0.5 mmol/kg potassium BW per hour should not be exceeded. Maximum daily dose The maximum recommended dose of potassium is 2 – 3 mmol/kg BW per 24 hours. In any case the limits for daily fluid intake must not be exceeded. Method of administration As a matter of principle, infusion pumps should be used for the infusion of potassium in the setting of correction therapy. Special precautions and warnings Solutions with low electrolyte content, especially sodium, should also be administered with care in patients with hyponatraemia. Care should be taken to avoid a rapid marked decrease of the serum sodium level as this may be associated with the risk of osmotic central nervous damage. Fluid balance, serum glucose, and other electrolytes may need to be monitored before and during administration, especially in patients with increased non-osmotic vasopressin release (syndrome of inappropriate antidiuretic hormone secretion, SIADH) and in patients co-medicated with vasopressin agonist drugs due to the risk of hyponatraemia. Monitoring of serum sodium is particularly important for physiologically hypotonic fluids. Potassium Chloride 0.15 % w/v and Glucose 5% w/v solution for infusion may become hypotonic after administration due to glucose and metabolisation in the body (see Summary of Product Characteristics sections 4.4., 4.5 and 4.8).
Paediatric population The infusion of hypotonic fluids together with the nonosmotic secretion of ADH (for example in pain, anxiety, the post-operative state, nausea, vomiting) may result in hyponatraemia. Treatment of an overdose Immediate interruption of the infusion, ECG monitoring, if necessary enhancement of urine flow and thus fluid and electrolyte excretion, administration of sodium bicarbonate and insulin. If insulin is given to increase cellular uptake of potassium, glucose should be given to avoid hypoglycaemia. In patients with persistent ECG abnormalities e.g. calcium gluconate may be administered to antagonize the cardiotoxic effects of potassium. Haemodialysis or peritoneal dialysis may be required in patients with renal insufficiency.
Incompatibilities In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. Shelf life after first opening the container From a microbiological point of view, unless the method of opening precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user. For complete information on this medicinal product please refer to the summary of product characteristics.
Frequently asked questions about Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion
How do I take Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion?
Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion comes as infusion. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion?
The active substance in Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion is potassium chloride, glucose monohydrate.
Are there equivalent medicines to Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion?
Medicines with the same active substance, strength and form include: 5% GLUCOSE INTRAVENOUS INFUSION SOLUTION, Potassium Chloride 0.15 % w/v and Glucose 10 % w/v Solution for Infusion BP, Potassium Chloride 0.15 % w/v and Glucose 5% w/v Solution for Infusion -BP. In total there are 26 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: potassium chloride, glucose monohydrate
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Supply of potassium to correct or prevent potassium deficiency and supply of glucose to cover basic energy requirements.
4.2. Posology and method of administration
Posology
The dosage is dependent on age, weight and clinical condition of the patient, especially those with renal or cardiac insufficiency. Fluid balance, serum glucose, serum sodium and other electrolytes may need to be monitored before and during administration, especially in patients with increased non-osmotic vasopressin release (syndrome of inappropriate antidiuretic hormone secretion, SIADH) and in patients co-medicated with vasopressin agonist drugs due to the risk of hyponatraemia.
Monitoring of serum sodium is particularly important for physiologically hypotonic fluids. Potassium Chloride 0.15 % w/v and Glucose 5% w/v Solution for Infusion may become hypotonic after administration due to glucose metabolisation in the body (see sections 4.4, 4.5 and 4.8).
Dosage and rate of infusion should be determined by ECG and serum electrolyte monitoring.
Adequate urine flow must be ensured.
Adults:
The following recommendations are general guidelines on potassium.
Potassium
The amount required for correction of moderate potassium deficiency and in maintenance may be calculated according to the following formula:
mmol K+required = (body weight [kg] × 0.2)* × 2 × (serum-K+target** – serum-K+actual [mmol/l])
*Term represents the extracellular fluid volume
** should be 4.5 mmol/l
The maximum recommended dose of potassium is 2 – 3 mmol/kgBW/24 h.
Fluid
Generally, not more than 40 ml fluid/kg BW/d should be supplied. In cases where more potassium is needed, other strengths should be considered as well.
Maximum infusion rate
Up to 5 ml/kg body weight per hour, corresponding to 0.25 g glucose/kg body weight per hour and 0.1-0.2 mmol/kg/ body weight per hour potassium (for 0.15% w/v and 0.3% w/v, respectively).
Paediatric population:
The volume and rate of infusion will depend upon the requirements of the individual patient. Reduced volumes and rates of infusion may be required. Generally a substitution rate of 0.5 mmol/kg potassium BW per hour should not be exceeded. Continuous ECG monitoring should be applied during infusion.
Maximum daily dose
The maximum recommended dose of potassium is 3 mmol/kg BW per 24 hours. In any case the limits for daily fluid intake must not be exceeded.
Elderly
Basically the same dosage as for adults applies, but caution should be exercised in patients suffering from further diseases like cardiac insufficiency or renal insufficiency that may frequently be associated with advanced age. See section 4.4.
Duration of use
This medicinal product may be administered as long as there is an indication for energy, potassium and fluid administration.
Method of administration
Intravenous use.
As a matter of principle, infusion pumps should be used for the infusion of potassium in the setting of correction therapy.
4.3. Contraindications
- Hyperkalaemia
- Severe renal impairment with oliguria and anuria
- Severe hyperchloraemia
- Head trauma (first 24 hours)
- Hyperhydration
- Hyperglycaemia
4.4. Special warnings and precautions for use
Special warnings
Solutions containing potassium should be administered slowly and only after renal function has been established and proved adequate. In patients with renal impairment, its use must be carefully controlled by frequent determinations of plasma potassium concentrations and periodic ECGs. The infusion must be discontinued if signs of renal insufficiency develop during infusion.
Potassium supplements should be administered with caution in patients with cardiac disease particularly in digitalised patients (see section 4.5).
Care must be exercised in the administration of large volume infusion of hypotonic fluids to patients with congested states or pulmonary oedema.
Solutions with low electrolyte content, especially sodium, should also be administered with care in patients with hyponatraemia.
Care should be taken to avoid a rapid marked decrease of the serum sodium level as this may be associated with the risk of osmotic central nervous damage.
Adequate sodium supplementation should be assured depending on the volume of Potassium Chloride 1.5 mg/ml (0.15 % w/v) and Glucose 50 mg/ml (5% w/v) Solution for Infusion to prevent hyponatraemia.
Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion is an isotonic solution. In the body, however, the solution can become physiologically hypotonic due to rapid glucose metabolisation (see section 4.2).
Depending on the tonicity of the solution, the volume and rate of infusion and depending on a patient's underlying clinical condition and capability to metabolise glucose, intravenous administration of these solutions can cause electrolyte disturbances most importantly hypo- or hyperosmotic hyponatraemia.
Hyponatraemia:
Patients with non-osmotic vasopressin release (e.g. in acute illness, pain, post-operative stress, infections, bums, and CNS diseases), patients with heart-, liver- and kidney diseases and patients exposed to vasopressin agonists (see section 4.5) are at particular risk of acute hyponatraemia upon infusion of hypotonic fluids.
Acute hyponatraemia can lead to acute hyponatraemic encephalopathy (brain oedema) characterized by headache, nausea, seizures, lethargy and vomiting. Patients with brain oedema are at particular risk of severe, irreversible and life-threatening brain injury.
Children, women in the fertile age and patients with reduced cerebral compliance (e.g. meningitis, intracranial bleeding, and cerebral contusion) are at particular risk of the severe and life-threatening brain swelling caused by acute hyponatraemia.
Caution should be exercised when the solution is administered to patients with diabetes, and in patients with impaired glucose tolerance for any other reason (see also section 4.5). Blood glucose monitoring will be required.
Due to the risk of developing a severe lactic acidosis and/or a Wernicke encephalopathy a preexisting thiamin (Vitamin B1) deficiency must be corrected before infusion of glucose containing solutions.
Solutions containing glucose should not be administered simultaneously with, before or after an administration of blood through the same infusion equipment because of the possibility of pseudoagglutination.
Administration of glucose solutions is not recommended after acute ischaemic strokes as hyperglycaemia was reported to worsen ischaemic brain damage and impair recovery.
Caution should be exercised in patients with disorders that are frequently associated with hyperkalaemia e.g. Addison's disease or sickle cell anaemia.
Paediatric population
Solutions with low salt, especially sodium, should only be administered with special caution to children and close monitoring of electrolyte and fluid balance should be performed.
Intravenous fluid therapy should be closely monitored in the paediatric population as they may have impaired ability to regulate fluids and electrolytes. The infusion of hypotonic fluids together with the non-osmotic secretion of ADH (for example in pain, anxiety, the post-operative state, nausea, vomiting) may result in hyponatraemia.
Elderly patients:
Elderly patients, who are more likely to suffer from cardiac insufficiency and renal impairment, should be closely monitored during treatment, and the dosage should be carefully adjusted, in order to avoid cardio circulatory and renal complications resulting from fluid overload.
Precautions for use
Clinical supervision should include ECGs, regular checks of fluid balance, serum electrolytes and monitoring of blood glucose.
4.5. Interaction with other medicinal products and other forms of interaction
• Digoxin, cardiac glycosides
In patients under treatment with cardiac glycosides care should be taken to keep the potassium concentration constant.
In case of hyperkalaemia - the effect of cardiac glycosides may be weakened, and in case of hypokalaemia it may result in cardiac glycoside toxicity. Potassium administration must be very carefully discontinued in these patients.
Interactions might occur in the concurrent administration of other antiarrytmics.
• Drugs with the potential to induce hyperkalaemia
Care should be taken in the concurrent use of drugs containing potassium and drugs with the potential to induce hyperkalaemia, such as:
– potassium-sparing diuretics e.g. spironolactone, triamterene
– ACE inhibitors
– AT1- receptor antagonists
– non-steroidal anti-inflammatory agents
– cyclosporine
– tacrolimus
– suxamethonium
The concomitant administration of potassium-containing solutions and these drugs may lead to severe hyperkalaemia, which may in turn lead to cardiac arrhythmia.
• Drugs leading to a decrease of the serum potassium level
ACTH, corticosteroids and loop diuretics can increase the renal elimination of potassium.
• Medicinal products leading to an increased vasopressin effect
The below listed drugs increase the vasopressin effect, leading to reduced renal electrolyte free water excretion and increase the risk of hospital acquired hyponatraemia following inappropriately balanced treatment with i. v. fluids (see sections 4.2, 4.4 and 4.8)
Drugs stimulating vasopressin release, e.g.:
Chlorpropamide, clofibrate, carbamazepine, vincristine, selective serotonin reuptake inhibitors, 3.4-methylenedioxy-N-methamphetamine , ifosfamide, antipsychotics, narcotics
Drugs potentiating vasopressin action, e.g.:
Chlorpropamide, NSAIDs, cyclophosphamide
Vasopressin analogues, e.g.:
Desmopressin, oxytocin, vasopressin, terlipressin
Other medicinal products increasing the risk of hyponatraemia also include diuretics in general and antiepileptics such as oxcarbazepine.
Other clinically relevant pharmacological drug interactions are not known.
4.6. Fertility, pregnancy and lactation
Pregnancy
There are no or limited amount of data from the use of Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion in pregnant women.
Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). However, as all components of Potassium Chloride 0.15 % w/v and Glucose 5% w/v Solution for Infusion are naturally present in the body and their biochemical properties are well known, no toxic effects in relation to pregnancy are to be expected.
Potassium Chloride 0.15 % w/v and Glucose 5% w/v Solution for Infusion can be used during pregnancy if clinically needed.
However, Potassium Chloride 0.15 % w/v and Glucose 5% w/v Solution for Infusion should be administrated with special caution for pregnant women during labour particularly if administered in combination with oxytocin due to the risk of hyponatraemia (see section 4.4, 4.5 and 4.8).
Breast-feeding
There are no or limited amount of data from the use of potassium chloride and glucose in lactating women.
However, as all components of this medicinal product are naturally present in the body and their biochemical properties are well known, no toxic effects in relation to lactation are to be expected.
Potassium Chloride 0.15 % w/v and Glucose 5% w/v Solution for Infusion can be used during breastfeeding if clinically needed.
Fertility
No data available.
4.7. Effects on ability to drive and use machines
Potassium Chloride 0.15 % w/v and Glucose 5% w/v Solution for Infusion has no or negligible influence on the ability to drive and use machines.
4.8. Undesirable effects
General
Undesirable effects are listed according to their frequencies as follows:
Very common (≥ 1/10)
Common (≥ 1/100 to < 1/10)
Uncommon (≥ 1/1,000 to < 1/100)
Rare (≥ 1/10,000 to < 1/1,000)
Very rare (< 1/10,000)
Not known (frequency cannot be estimated from the available data).
General disorders and administration site conditions
Not known: Local reactions at the infusion site, including local pain, venous irritation and occasionally thrombophlebitis may occur.
Metabolism and nutrition disorders
Not known: Hospital Acquired Hyponatraemia
Neurological disorders:
Not known: Hyponatraemic encephalopathy
Hospital acquired hyponatraemia may cause irreversible brain injury and death due to development of acute hyponatraemic encephalopathy (see sections 4.2 and 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
Symptoms
In case of overdose hyperkalaemia, hyponatraemia, hyperhydration, hyperglycaemia, potassium intoxication, oedema, metabolic and electrolyte disorders can result
The symptoms of hyperkalaemia are primarily cardiovascular disorders and include hypotension, cardiac arrhythmia, heart block, ECG abnormalities with development of biphasic curves and cardiac arrest. Other symptoms include paresthesias of extremities, muscle or respiratory paralysis, areflexia, weakness and mental confusion.
Treatment
Immediate interruption of the infusion, ECG monitoring, if necessary enhancement of urine flow and thus fluid and electrolyte excretion, administration of sodium bicarbonate and insulin. If insulin is given to increase cellular uptake of potassium, glucose should be given to avoid hypoglycaemia. In patients with persistent ECG abnormalities e.g. calcium gluconate may be administered to antagonize the cardiotoxic effects of potassium. Haemodialysis or peritoneal dialysis may be required in patients with renal insufficiency.
💬 Ask about this leaflet
Ask anything about Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.